Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its poor prognosis and lack of targeted therapies.
• Immunotherapy, particularly targeting the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) pathway, has shown promise in cancer treatment.
• Current PD-1/PD-L1 targeted therapies often utilize monoclonal antibodies (mAbs), which have associated drawbacks.

Purpose of the Study:

• To review the PD-1/PD-L1 interaction in the context of cancer immunotherapy.
• To summarize existing monoclonal antibodies (mAbs) and aptamer-based therapeutics targeting PD-1 and PD-L1.
• To highlight the potential of aptamers as an alternative therapeutic strategy for PD-1/PD-L1 modulation.

Main Methods:

• Literature review of PD-1/PD-L1 interaction mechanisms.
• Comparative analysis of monoclonal antibodies (mAbs) and aptamers for PD-1/PD-L1 targeting.
• Discussion of the advantages and disadvantages of each therapeutic modality.

Main Results:

• Monoclonal antibodies (mAbs) are the current standard for PD-1/PD-L1 targeted therapy but face challenges including immunological reactions, costly production, and cold chain requirements.
• Aptamers, as nucleotide-based molecules, demonstrate high specificity and selectivity for their targets.
• The small size of aptamers facilitates better tissue penetration compared to mAbs.

Conclusions:

• Aptamers present a viable alternative to monoclonal antibodies for modulating PD-1/PD-L1 interactions.
• Aptamers address key limitations associated with current mAb therapies, offering potential for improved treatment efficacy and delivery.
• Aptamer-based strategies represent a promising future direction for developing novel immunotherapies for cancers like TNBC.